V 
Vertex Pharmaceuticals VRTX · USD
Health Care · Biotechnology · US listing · 🇺🇸 United States
S&P 500Nasdaq-100
550.87
+0.69%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vertex Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Vertex Pharmaceuticals is based in Boston, Massachusetts and is incorporated in Massachusetts. Its shares trade on Nasdaq under the ticker VRTX. It is a member of the S&P 500 and Nasdaq-100. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $12.00bn and net income of $3.95bn. At that date it held total assets of $25.64bn and shareholders' equity of $18.67bn.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Jul 1991
- Employees
- 6,400
- Website
- vrtx.com ↗
- Head office
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Incorporated in
- MA
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Jeffrey LeidenExecutive Chairman of the Board, since 2009$6.6m
- Dr. Reshma KewalramaniPresident, Chief Executive Officer, Director, since 2018$21.5m
- Mr. Charles WagnerChief Financial Officer, Chief Operating Officer, Executive Vice President$8.0m
- Dr. David AltshulerExecutive Vice President, Chief Scientific Officer, since 2012$7.6m
- Dr. E. Morrow AtkinsonExecutive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Science and Manufacturing Operations
- Mr. Jonathan BillerExecutive Vice President, Chief Legal Officer
- Dr. Carmen BozicExecutive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
- Mr. Duncan MckechnieExecutive Vice President, Chief Commercial Officer
- Mr. Amit SachdevExecutive Vice President, Chief Patient and External Affairs Officer$6.2m
- Dr. Ourania TatsisExecutive Vice President, Chief Regulatory and Quality Officer$7.3m
- Ms. Kristen AmbroseSenior Vice President, Chief Accounting Officer
- Ms. Joy LiuCorporate Secretary
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 75
- Environment
- 90
- Social
- 99
- Governance
- 35
- Direct emissions (scope 1)
- 8,976 t
- Energy emissions (scope 2)
- 16,117 t
- Value chain emissions (scope 3)
- 551,647 t
- Women in the workforce
- 55%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vertex Pharmaceuticals Inc has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company holds a strong portfolio of innovative and breakthrough drugs, particularly for the treatment of cystic fibrosis. These drugs have not only garnered significant market share but have also improved the quality of life for patients worldwide.
- Secondly, Vertex Pharmaceuticals has established strong relationships with healthcare professionals, research institutions, and advocacy groups. These collaborations enable the company to stay at the forefront of scientific advancements and ensure the development of effective treatment options.
- Lastly, the company demonstrates a robust financial position with steady revenue growth and a solid pipeline of potential drugs. This financial strength allows Vertex Pharmaceuticals to invest in research and development, ensuring continued innovation and expansion of its product offerings.
Weaknesses
- Despite its strengths, Vertex Pharmaceuticals Inc also faces certain weaknesses. One major weakness is its heavy reliance on a few flagship drugs, especially those targeting cystic fibrosis. As a result, the company is exposed to market risks and regulatory uncertainties specifically associated with these drugs. Any setbacks or challenges related to these products could significantly impact the company's revenues and growth prospects.
- Additionally, Vertex Pharmaceuticals operates in a highly competitive industry. Competition from other pharmaceutical companies, both established players and emerging biotech firms, poses a continuous threat to its market position. This necessitates a continual focus on innovation and differentiation to remain ahead of the competition.
Opportunities
- The pharmaceutical industry offers numerous opportunities for Vertex Pharmaceuticals to further expand and solidify its position. The growing global prevalence of cystic fibrosis and other genetic disorders presents an opportunity for increased demand for the company's existing and future drugs. By strategically leveraging its expertise in disease biology, Vertex can identify new therapeutic targets and develop novel treatments for other genetic diseases.
- Moreover, the increasing adoption of precision medicine and personalized therapies presents a favorable environment for Vertex Pharmaceuticals. The ability to tailor treatments to individual patients based on their genetic makeup aligns with the company's core competency in developing targeted therapies.
Threats
- Despite the opportunities, Vertex Pharmaceuticals Inc faces potential threats that could impact its growth and profitability. One significant threat is the intense scrutiny and regulation of the pharmaceutical industry. Stricter regulations, pricing pressures, and reimbursement challenges can limit market access and profitability for new drugs.
- Another threat comes from potential legal and intellectual property issues. Vertex operates in multiple countries, each with its own patent laws and litigation risks. Any legal disputes or challenges to its patents can lead to substantial financial losses and a loss of market exclusivity for certain drugs.
- Furthermore, the current global economic landscape and geopolitical uncertainties can also impact the company's operations, including manufacturing costs, supply chain disruptions, and market demand fluctuations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.